{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:03:47Z","timestamp":1789488227404,"version":"build-2803163510"},"reference-count":144,"publisher":"SAABRON PRESS","issue":"3","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Anti-CD38 monoclonal antibodies (mAbs), including daratumumab and isatuximab, have become key components of treatment for relapsed\/refractory multiple myeloma (RRMM). This expert consensus provides evidence-based guidance on their optimal use, including regimen selection, special considerations for elderly or frail patients, and the treatment of high-risk subgroups. Key topics addressed include the selection of anti-CD38-based regimens, patient stratification by frailty and comorbidities, strategies for managing hematologic toxicities, and considerations for re-treatment. Anti-CD38 mAb-based regimens have demonstrated clinical efficacy across diverse RRMM populations, including patients with high-risk cytogenetic abnormalities such as 1q21+. While resistance remains a clinical challenge, particularly in previously exposed patients, current evidence supports the feasibility of anti-CD38 mAb rechallenge following a substantial washout period (typically 6 to 12 months), which may allow partial recovery of CD38 expression and immune effector function. The consensus also emphasizes the continued utility of these agents in elderly or frail individuals, where durable responses can be achieved with appropriate monitoring and supportive care. Moreover, anti-CD38 mAbs are recognized as key components within evolving treatment paradigms, supporting their use for combination strategies involving emerging immunotherapies such as CAR-T cells and bispecific antibodies. This consensus provides a framework to guide individualized treatment decisions and highlights the need for continued research to optimize the integration of anti-CD38 mAbs into the modern therapeutic landscape of RRMM.<\/jats:p>","DOI":"10.46989\/001c.141401","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T15:56:48Z","timestamp":1754668608000},"source":"Crossref","is-referenced-by-count":5,"title":["Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed\/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group"],"prefix":"10.46989","volume":"7","author":[{"given":"Wenming","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijingk, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chor Sang","family":"Chim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hong Kong Sanatorium Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"National University Cancer Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Aichi Medical University, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Shang-Yi","family":"Huang","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Ptushkin","sequence":"additional","affiliation":[{"name":"Botkin Moscow City Clinical Hospital, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00yw7a334","id-type":"ROR","asserted-by":"publisher"}],"name":"Nerima Hikarigaoka Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Siu Ming","family":"Wong","sequence":"additional","affiliation":[{"name":"Sir Y.K. Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1240318","DOI":"10.3389\/fonc.2023.1240318","article-title":"Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials","volume":"13","author":"L., et al. Ye","year":"2023","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1400101","DOI":"10.3389\/fimmu.2024.1400101","article-title":"Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study","volume":"15","author":"Y., et al. Zhang","year":"2024","journal-title":"Front Immunol"},{"issue":"7","key":"ref3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nurpra.2022.05.001","article-title":"CD38 Monoclonal Antibodies in Relapsed\/Refractory Multiple Myeloma","volume":"18","author":"D., et al. Verina","year":"2022","journal-title":"The Journal for Nurse Practitioners"},{"issue":"10","key":"ref4","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"X., et al. Leleu","year":"2022","journal-title":"Ann Hematol"},{"issue":"8","key":"ref5","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"M. A., et al. Dimopoulos","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"ref6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00277-017-3191-7","article-title":"Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?","volume":"97","author":"X., et al. Leleu","year":"2018","journal-title":"Ann Hematol"},{"issue":"19","key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194978","article-title":"Management of Adverse Events and Supportive Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"13","author":"S., et al. Pozzi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"24","key":"ref8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/nejm199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"H., et al. Ludwig","year":"1990","journal-title":"N Engl J Med"},{"issue":"7","key":"ref9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/14737140.2017.1330153","article-title":"Increased risk of arterial thromboembolic events with combination lenalidomide\/dexamethasone therapy for multiple myeloma","volume":"17","author":"S., et al. Maharaj","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/cncr.26302","article-title":"Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis","volume":"118","author":"E. J., et al. Anaissie","year":"2012","journal-title":"Cancer"},{"issue":"18","key":"ref11","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"S. V., et al. Rajkumar","year":"2011","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"19","key":"ref12","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"R. Knight","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"K., et al. Piedra","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"ref14","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis","volume":"126","author":"R., et al. Chakraborty","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"ref15","doi-asserted-by":"publisher","first-page":"ofac574","DOI":"10.1093\/ofid\/ofac574","article-title":"Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis","volume":"9","author":"S., et al. Vassilopoulos","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"ref16","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"N. S., et al. Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"ref17","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"I. M., et al. Otani","year":"2022","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"ref18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ajh.27206","article-title":"Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA","volume":"99","author":"E., et al. Terpos","year":"2024","journal-title":"American Journal of Hematology"},{"issue":"7","key":"ref19","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3324\/haematol.2023.284089","article-title":"Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study","volume":"109","author":"V., et al. Gonz\u00e1lez-Calle","year":"2024","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"ref20","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/blood-2022-162733","article-title":"MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab \u00b1 Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed\/Refractory Multiple Myeloma Following \u22651 Prior Line of Therapy","volume":"140","author":"Y. C., et al. Cohen","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"ref21","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1182\/blood-2022-157713","article-title":"Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"P., et al. Rodr\u00edguez Otero","year":"2022","journal-title":"Blood"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"P. Sonneveld","year":"2017","journal-title":"Hematology 2014, the American Society of Hematology Education Program Book"},{"issue":"Supplement 1","key":"ref23","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/blood-2023-181266","article-title":"Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and\/or Refractory MM (RRMM)","volume":"142","author":"B., et al. Dhakal","year":"2023","journal-title":"Blood"},{"issue":"9","key":"ref24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/jco.2017.75.5207","article-title":"Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma","volume":"36","author":"D. T., et al. Vogl","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"ref25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First Global Approval","volume":"79","author":"Y. Y. Syed","year":"2019","journal-title":"Drugs"},{"issue":"10262","key":"ref26","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"S., et al. Grosicki","year":"2020","journal-title":"The Lancet"},{"issue":"1","key":"ref27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"A. J. Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"ref28","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"S. M., et al. Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"ref29","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3324\/haematol.2024.285916","article-title":"Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study","volume":"110","author":"A., et al. Bobin","year":"2025","journal-title":"Haematologica"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843612.41180.42","article-title":"S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED\/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL","volume":"6","author":"C., et al. Hasselbalch Riley","year":"2022","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"ref31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2022-159707","article-title":"Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Phase 1\/2 Results from MonumenTAL-1","volume":"140","author":"A., et al. Chari","year":"2022","journal-title":"Blood"},{"issue":"24","key":"ref32","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"A., et al. Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"ref33","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1186\/s12889-022-14412-1","article-title":"Worldwide cancer statistics of adults over 75 years old in 2019: a systematic analysis of the global burden of disease study 2019","volume":"22","author":"D., et al. Xiang","year":"2022","journal-title":"BMC Public Health"},{"issue":"16_suppl","key":"ref34","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results","volume":"41","author":"B. R., et al. Dholaria","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"ref35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"P., et al. Moreau","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"Supplement 1","key":"ref36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/blood-2024-200181","article-title":"Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies","volume":"144","author":"A., et al. D'Souza","year":"2024","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"E. J., et al. Smith","year":"2015","journal-title":"Sci Rep"},{"issue":"5","key":"ref38","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"D. J., et al. DiLillo","year":"2021","journal-title":"Blood Adv"},{"issue":"22","key":"ref39","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/jco.24.01008","article-title":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"N., et al. Bumma","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"ref40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/jha2.743","article-title":"Difficult-to-treat patients with relapsed\/refractory multiple myeloma: A review of clinical trial results","volume":"4","author":"M. S., et al. Raab","year":"2023","journal-title":"EJHaem"},{"issue":"12","key":"ref41","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1080\/10428194.2021.1941927","article-title":"Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma","volume":"62","author":"D., et al. Siegel","year":"2021","journal-title":"Leukemia & Lymphoma"},{"issue":"4","key":"ref42","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ajh.26480","article-title":"Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with pomalidomide and dexamethasone\u00b1subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial","volume":"97","author":"E., et al. Terpos","year":"2022","journal-title":"American Journal of Hematology"},{"issue":"4","key":"ref43","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/jpm14040360","article-title":"Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials","volume":"14","author":"FCAd., et al. Moraes","year":"2024","journal-title":"Journal of Personalized Medicine"},{"issue":"6","key":"ref44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/bmt.2008.180","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"S., et al. Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"16_suppl","key":"ref45","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1200\/JCO.2022.40.16_suppl.8025","article-title":"Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed\/refractory multiple myeloma (RRMM): Interim phase 1b study results","volume":"40","author":"H., et al. Quach","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"ref46","doi-asserted-by":"publisher","first-page":"4757.2","DOI":"10.1182\/blood-2024-203880","article-title":"Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma (SubQSA)","volume":"144","author":"T. T., et al. Buck","year":"2024","journal-title":"Blood"},{"issue":"4","key":"ref47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/nejmoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"J., et al. San-Miguel","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"ref48","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/nejmoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"P., et al. Rodriguez-Otero","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"ref49","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"A. M., et al. Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"ref50","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/leu.2017.331","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"S. K., et al. Kumar","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"ref51","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.clml.2019.10.014","article-title":"Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma","volume":"20","author":"E., et al. Kastritis","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"ref52","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.16793","article-title":"Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma","volume":"193","author":"C., et al. Bygrave","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"ref53","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"J., et al. Corre","year":"2020","journal-title":"Haematologica"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"Jco2401253","DOI":"10.1200\/jco-24-01253","article-title":"Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed\/Refractory Multiple Myeloma","author":"M. F., et al. Kaiser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref55","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"S. V. Rajkumar","year":"2024","journal-title":"American Journal of Hematology"},{"issue":"11","key":"ref56","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"A. Palumbo","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","author":"M. A., et al. Dimopoulos","year":"2025","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"9","key":"ref58","doi-asserted-by":"publisher","first-page":"e0136207","DOI":"10.1371\/journal.pone.0136207","article-title":"Double Relapsed and\/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs","volume":"10","author":"S., et al. Gooding","year":"2015","journal-title":"PLOS ONE"},{"issue":"2","key":"ref59","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"C. S., et al. Chim","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"ref60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor\u2013mediated cross-linking","volume":"197","author":"M. B., et al. Overdijk","year":"2016","journal-title":"The Journal of Immunology"},{"issue":"3","key":"ref61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"H. C., et al. Adams III","year":"2019","journal-title":"Cytometry Part A"},{"issue":"2","key":"ref62","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"T., et al. Casneuf","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"ref63","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3324\/haematol.2020.268656","article-title":"Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma","volume":"106","author":"M., et al. Kinder","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"ref64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"M. B., et al. Overdijk","year":"2015","journal-title":"mAbs"},{"issue":"12","key":"ref65","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cells8121522","article-title":"Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab","volume":"8","author":"T. G., et al. Martin","year":"2019","journal-title":"Cells"},{"issue":"10","key":"ref66","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.ccr-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"L., et al. Moreno","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"ref67","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"D. Kazandjian","year":"2016","journal-title":"Seminars in Oncology"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"C., et al. Zhu","year":"2020","journal-title":"Frontiers in immunology"},{"issue":"5","key":"ref69","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/hon.3041","article-title":"Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant","volume":"40","author":"C., et al. Botta","year":"2022","journal-title":"Hematological Oncology"},{"issue":"14","key":"ref70","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"S. Z., et al. Usmani","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"ref71","doi-asserted-by":"publisher","first-page":"e741","DOI":"10.1016\/S2352-3026(24)00148-0","article-title":"Isatuximab plus carfilzomib\u2013dexamethasone versus carfilzomib\u2013dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial","volume":"11","author":"K., et al. Yong","year":"2024","journal-title":"The Lancet Haematology"},{"issue":"10","key":"ref72","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"M. A., et al. Dimopoulos","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"3","key":"ref73","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"P. G., et al. Richardson","year":"2022","journal-title":"The Lancet Oncology"},{"issue":"7001","key":"ref74","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Qualitative Research: Consensus methods for medical and health services research","volume":"311","author":"J. Jones","year":"1995","journal-title":"BMJ"},{"issue":"9","key":"ref75","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2105\/ajph.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"A., et al. Fink","year":"1984","journal-title":"American Journal of Public Health"},{"issue":"7650","key":"ref76","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"G. H., et al. Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"ref77","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/bjh.19627","article-title":"Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence","volume":"205","author":"M. A., et al. Hartley-Brown","year":"2024","journal-title":"British Journal of Haematology"},{"issue":"12","key":"ref78","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"S. V., et al. Rajkumar","year":"2014","journal-title":"The lancet oncology"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/ITT.S259122","article-title":"CD38-Directed Therapies for Management of Multiple Myeloma","volume":"10","author":"H., et al. Hashmi","year":"2021","journal-title":"ImmunoTargets and Therapy"},{"issue":"13","key":"ref80","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"H. M., et al. Lokhorst","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"10027","key":"ref81","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"S., et al. Lonial","year":"2016","journal-title":"The Lancet"},{"issue":"1","key":"ref82","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"S. Z., et al. Usmani","year":"2016","journal-title":"Blood"},{"issue":"23","key":"ref83","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1182\/blood.V126.23.3015.3015","article-title":"MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds","volume":"126","author":"R., et al. Boxhammer","year":"2015","journal-title":"Blood"},{"issue":"20","key":"ref84","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"P. L., et al. Fedele","year":"2018","journal-title":"Blood"},{"issue":"1","key":"ref85","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"S. Z., et al. Usmani","year":"2022","journal-title":"The Lancet Oncology"},{"issue":"1","key":"ref86","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"T., et al. Martin","year":"2023","journal-title":"Blood Cancer Journal"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1182\/blood-2022-163483","article-title":"Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study","volume":"140","author":"M. A., et al. Dimopoulos","year":"2022","journal-title":"Blood"},{"issue":"6","key":"ref88","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"M. A., et al. Dimopoulos","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"1","key":"ref89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"R. L., et al. Siegel","year":"2023","journal-title":"CA: a cancer journal for clinicians"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"106576","DOI":"10.1016\/j.leukres.2021.106576","article-title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis","volume":"104","author":"S., et al. Bringhen","year":"2021","journal-title":"Leuk Res"},{"issue":"10214","key":"ref91","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/s0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"M., et al. Attal","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"ref92","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1182\/bloodadvances.2022008866","article-title":"Phase 1\/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma","volume":"7","author":"B. A., et al. Derman","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"ref93","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"H., et al. Yimer","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"ref94","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1080\/10428194.2022.2076847","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study","volume":"63","author":"H., et al. Yimer","year":"2022","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"ref95","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/ph18020145","article-title":"Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma","volume":"18","author":"I., et al. Sorgiovanni","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"Supplement 1","key":"ref96","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.1182\/blood-2023-185792","article-title":"Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03","volume":"142","author":"A., et al. Bobin","year":"2023","journal-title":"Blood"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"20406207251314289","DOI":"10.1177\/20406207251314289","article-title":"Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis","volume":"16","author":"M., et al. Osama","year":"2025","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"ref98","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"U. H., et al. Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"ref99","doi-asserted-by":"publisher","first-page":"e1486948","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","author":"J., et al. Ghose","year":"2018","journal-title":"OncoImmunology"},{"issue":"1","key":"ref100","doi-asserted-by":"publisher","first-page":"104262","DOI":"10.1016\/j.lpm.2024.104262","article-title":"Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma","volume":"54","author":"A. Perrot","year":"2025","journal-title":"La Presse M\u00e9dicale"},{"issue":"21","key":"ref101","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"O., et al. Perez de Acha","year":"2023","journal-title":"Blood Advances"},{"issue":"5","key":"ref102","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab","volume":"11","author":"J., et al. Mikhael","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"ref103","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00277-023-05218-1","article-title":"Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment","volume":"102","author":"T., et al. Kikuchi","year":"2023","journal-title":"Annals of Hematology"},{"issue":"Supplement 1","key":"ref104","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-140526","article-title":"Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"M. R., et al. Becnel","year":"2020","journal-title":"Blood"},{"issue":"2","key":"ref105","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.1002\/hon.70042","article-title":"Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study","volume":"43","author":"E. A., et al. Martino","year":"2025","journal-title":"Hematological Oncology"},{"issue":"7","key":"ref106","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/s1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"M. A., et al. Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"ref107","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: incidence, correlations, and prognostic significance","volume":"48","author":"V., et al. Eleutherakis-Papaiakovou","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"ref108","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1038\/bcj.2014.55","article-title":"Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis","volume":"4","author":"J., et al. Lu","year":"2014","journal-title":"Blood Cancer J"},{"issue":"10","key":"ref109","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020","volume":"17","author":"S.K., et al. Kumar","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"ref110","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/jco.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"J., et al. Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref111","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"M., et al. Sant","year":"2014","journal-title":"The Lancet Oncology"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"167125","DOI":"10.1155\/2014\/167125","article-title":"Pathogenesis of renal failure in multiple myeloma: any role of contrast media?","volume":"2014","author":"M. Mussap","year":"2014","journal-title":"Biomed Res Int"},{"issue":"6","key":"ref113","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1080\/10428194.2020.1867725","article-title":"Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019","volume":"62","author":"G. R., et al. Mohyuddin","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"ref114","doi-asserted-by":"publisher","first-page":"2399430","DOI":"10.1080\/16078454.2024.2399430","article-title":"Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis","volume":"29","author":"H., et al. Jiang","year":"2024","journal-title":"Hematology"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"20406207251319593","DOI":"10.1177\/20406207251319593","article-title":"Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis","volume":"16","author":"H., et al. Bai","year":"2025","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"ref116","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1016\/j.clml.2024.07.007","article-title":"Pomalidomide Use and Kidney Outcomes in Patients With Relapsed\/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study","volume":"24","author":"A., et al. Meraz-Munoz","year":"2024","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"11","key":"ref117","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-020-00381-4","article-title":"Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients","volume":"10","author":"D., et al. Fotiou","year":"2020","journal-title":"Blood Cancer Journal"},{"issue":"6","key":"ref118","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3324\/haematol.2021.279229","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis","volume":"107","author":"M., et al. Capra","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"ref119","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"M. A., et al. Dimopoulos","year":"2017","journal-title":"The Lancet Oncology"},{"issue":"11","key":"ref120","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.3390\/cancers12113106","article-title":"Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients","volume":"12","author":"F. Bonello","year":"2020","journal-title":"Cancers"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/cia.S89465","article-title":"Multiple myeloma in the very elderly patient: challenges and solutions","volume":"11","author":"J., et al. Willan","year":"2016","journal-title":"Clin Interv Aging"},{"issue":"4","key":"ref122","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"L. J., et al. Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"ref123","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3324\/haematol.2019.217448","article-title":"Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies","volume":"105","author":"M. V., et al. Mateos","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"ref124","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hon.3038","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis","volume":"40","author":"T., et al. Facon","year":"2022","journal-title":"Hematological Oncology"},{"issue":"4","key":"ref125","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3324\/haematol.2020.253450","article-title":"Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed\/refractory multiple myeloma: ICARIA-MM subgroup analysis","volume":"106","author":"F. H., et al. Schjesvold","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"ref126","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"A., et al. Chari","year":"2017","journal-title":"Blood"},{"key":"ref127","article-title":"NCT03158688, C.g.i. Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and\/or Refractory Multiple Myeloma. (CANDOR)"},{"key":"ref128","article-title":"NCT03275285, C.g.i. Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And\/Or Refractory Multiple Myeloma Patients (IKEMA)"},{"issue":"24","key":"ref129","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"P., et al. Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"4","key":"ref130","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"T. M. Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"ref131","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"I., et al. Hanamura","year":"2006","journal-title":"Blood"},{"issue":"12","key":"ref132","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","article-title":"Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies","volume":"14","author":"K., et al. Bisht","year":"2021","journal-title":"Expert Review of Hematology"},{"issue":"3","key":"ref133","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"M., et al. Binder","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"ref134","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061360","article-title":"Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets","volume":"10","author":"J., et al. Burroughs Garc\u00eca","year":"2021","journal-title":"Cells"},{"issue":"9","key":"ref135","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.26639","article-title":"Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications","volume":"97","author":"E., et al. Kastritis","year":"2022","journal-title":"Am J Hematol"},{"issue":"11","key":"ref136","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1634\/theoncologist.2019-0132","article-title":"1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China","volume":"24","author":"X., et al. Li","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"ref137","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14712598.2024.2357382","article-title":"Anti-CD38 monoclonal antibodies in multiple myeloma with gain\/amplification of chromosome arm 1q: a review of the literature","volume":"24","author":"E., et al. Barbieri","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"Supplement 1","key":"ref138","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1182\/blood-2022-168848","article-title":"Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study","volume":"140","author":"J. L., et al. Kaufman","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"ref139","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1182\/blood-2023-173896","article-title":"Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries","volume":"142","author":"K. J. C., et al. Lim","year":"2023","journal-title":"Blood"},{"issue":"1","key":"ref140","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","author":"M., et al. Mohan","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"10","key":"ref141","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3324\/haematol.2022.280660","article-title":"Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA","volume":"107","author":"T., et al. Martin","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"ref142","doi-asserted-by":"publisher","first-page":"e3258","DOI":"10.1002\/hon.3258","article-title":"Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed\/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study","volume":"42","author":"T., et al. Facon","year":"2024","journal-title":"Hematological Oncology"},{"issue":"34","key":"ref143","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.2217\/fon-2021-0568","article-title":"Isatuximab for Relapsed\/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study","volume":"17","author":"P. G., et al. Richardson","year":"2021","journal-title":"Future Oncology"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.12.002","article-title":"Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody","author":"K., et al. Ramasamy","year":"2024","journal-title":"Clinical Lymphoma Myeloma and Leukemia"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/141401-consensus-guidelines-and-recommendations-for-the-anti-cd38-based-therapy-in-clinical-practice-for-relapsed-refractory-multiple-myeloma-from-the-pan-p","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:17:38Z","timestamp":1789485458000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/141401-consensus-guidelines-and-recommendations-for-the-anti-cd38-based-therapy-in-clinical-practice-for-relapsed-refractory-multiple-myeloma-from-the-pan-p"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":144,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.141401","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}